Genmab duobody DuoBody-PD-L1×4-1BB, a first-in-class, bispecific, next-generation May 8, 2018 · Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale. Genmab A/S Carl May 24, 2023 · 一种CD3/CD20 IgG1双抗，使用Genmab专有的DuoBody技术创建，可同时结合T细胞上的CD3和B细胞上的CD20，并诱导T 细胞靶向杀伤肿瘤细胞。DuoBody是Genmab许多双抗产品和企业合作的基础，是一种双抗生成技术，能够快速、稳定且规模化生产双抗。 May 8, 2018 · Genmab Enters Commercial DuoBody Technology Agreement with BioNovion in the Field of Immuno-Oncology . Genmab's DuoBody-CD3 technology is designed to direct cytotoxic Sep 21, 2020 · Teclistamab is a humanized immunoglobulin G4-proline, alanine, alanine (IgG-4 PAA) bispecific DuoBody antibody (Genmab). : epcoritamab (EPKINLY ® / TEPKINLY ®) • BioNTech SE. About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and May 8, 2018 · Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale. 4-1BB co-stimulation can activate cytotoxic T-cell- and NK-cell-mediated anti-tumor immunity and has been shown to synergize Apr 17, 2023 · Media Release COPENHAGEN, Denmark; April 17, 2023 Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies; Discovery programs against two differentiated targets are underway; Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) GEN1042 (DuoBody-CD40x4-1BB) is an investigational, novel, agonistic bispecific antibody that combines targeting and conditional activation of CD40 and 4-1BB on immune cells. com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U. Dec 31, 2023 · Genmab’s operating expenses increased by DKK 2,689 million, or 33%, from DKK 8,238 million in 2022 to DKK 10,927 million in 2023, driven by the increase and accelerated advancement of epcoritamab under our collaboration with AbbVie, advancement of acasunlimab and DuoBody-CD40x4-1BB under our collaboration with BioNTech, further progression of May 2, 2022 · DuoBody-PD-L1×4-1BB (GEN1046) is a first-in-class bispecific immunotherapy with a manageable safety profile and encouraging preclinical and early clinical activity. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T News for GEN1047 / Genmab. Methods: T-cell activation and T-cell-mediated cytotoxicity were measured by flow cytometry following co-culture with tumour Genmab Technology Our novel HexElect ® technology platform further builds on our expertise in antibody clustering, and consists of two components designed to work together as a team. Below is a summary of business progress in Feb 18, 2021 · Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. S. Genmab reasons that dual-targeting may improve binding specificity and efficacy in inactivating disease targets. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 with the Y-shaped Genmab logo ®; HuMax ®; DuoBody Jun 9, 2022 · DuoBody ®平台用于发现和开发治疗用双特异性抗体，为多种双靶向应用提供了灵活的解决方案。该平台基于人体免疫系统中IgG4抗体Fab臂交换的独特机制，Genmab对该机制进行了深入研究，最终开发了可以稳定产生双特异性IgG1抗体的平台技术 May 14, 2024 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. DuoBody-CD3x5T4 is a bispecific IgG1 antibody with a functionally inactive Fc Apr 4, 2023 · Abstract. Genmab has initiated a First-in-Human clinical trial to evaluate the safety and preliminary efficacy of DuoBody-CD3xCD20 by subcutaneous administration in patients with B-cell malignancies. Acasunlimab (DuoBody Aug 10, 2016 · Genmab said today its DuoBody® technology platform will be used by Gilead Sciences to create bispecific antibody candidates targeting HIV, under a licensing deal that could generate up to $282 Apr 3, 2024 · Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody Dec 12, 2024 · Characterization of DuoBody-CD40×4-1BB in vitro was performed in a broad range of functional immune cell assays, including cell-based reporter assays, T-cell proliferation assays, mixed-lymphocyte reactions and tumor-infiltrating lymphocyte assays Mar 2, 2020 · Genmab拥有4类抗体药物研发平台：基于UltiMAb的裸抗体药物平台HuMAb、 双特异性抗体平台DuoBody 、增强型抗体平台HexaBody以及强增强型抗体平台HexElect。此外，Genmab还与ADC Therapeutics（ADCT）达成合作，共同开发基于公司HuMax-TAC的 Oct 31, 2014 · And Genmab's DuoBody platform uses matched point mutations at the heavy-chain interface of two separate antibodies to drive recombination of the antigen-binding fragments of the antibody and Fc May 24, 2024 · About Epcoritamab Epcoritamab-bysp is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab works with resourceful and like-minded partners on our quest to develop the next generation of antibody therapeutics. May 8, 2018 · Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated effector Aug 14, 2015 · Genmab said today it has agreed to license its DuoBody technology platform to Novo Nordisk to create and develop bispecific antibody candidates for two therapeutic programs “outside of cancer Dec 9, 2024 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and Aug 5, 2024 · Acasunlimab (GEN1046) is an investigational PD-L1x4-1BB bispecific antibody fusing Genmab's proprietary DuoBody ® technology platform and BioNTech’s proprietary immunomodulatory antibodies Dec 12, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cells. We previously showed that GEN1042 induces conditional CD40 and 4-1BB agonist activity, leading to Aug 14, 2015 · The DuoBody platform is Genmab's proprietary technology platform for the discovery and development of bispecific antibodies. Nov 6, 2024 · Partners for Genmab owned products ≥50%: • Pfizer Inc. Cell lines, commercially available antibodies and research antibodies produced at Genmab are Jan 13, 2025 · solid tumors that were treated with DuoBody-CD40×4- 1BB in the dose-escalation phase of the first-in-human clinical trial (NCT04083599). DuoBody®-CD40×4-1BB (GEN1042) is a first-in-class bispecific agonistic antibody that combines targeting of costimulatory molecules CD40 and 4-1BB, resulting in priming and (re-)activation Jun 1, 2024 · Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an Genmab is an international biotech company specializing in antibody therapeutics for the treatment of cancer and other serious diseases Dec 10, 2023 · Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is Nov 29, 2018 · Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, Genmab has initiated a First-in-Human clinical trial to evaluate the safety and preliminary efficacy of DuoBody-CD3xCD20 by subcutaneous administration in patients with B-cell malignancies. The choice of an appropriate tumor Sep 22, 2020 · Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody ® platform for generation of bispecific antibodies, the HexaBody ® platform, which creates effector function enhanced antibodies, the HexElect ® platform, which combines two co-dependently acting HexaBody molecules to introduce Nov 1, 2022 · Generation of DuoBody-CD3x5T4. Today, several DBs are in clinical development and amivantamab, Huang et al. DuoBody Technology is distinct from other dual-targeting technologies. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20 Dec 1, 2023 · Abstract. AbbVie’s ADC technology allows the Dec 2, 2016 · To target cancer cells expressing BCMA, we developed a BCMAxCD3 bispecific antibody using the Genmab DuoBody® technology (Ab-957) to recruit T cells to BCMA-expressing MM cells so that T cells could be activated and induced to kill BCMA+ cancer DuoBody-PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology. [VIRTUAL] Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models (SITC 2020) - P1/2 | "In humanized CDX and PDX mouse models, DuoBody-CD3x5T4 showed anti-tumor activity, in addition to PD biomarkers associated with T-cell activation in the Genmab AS Original Assignee Genmab AS Priority date (The priority date is an assumption and is not a legal conclusion. genmab. GEN1042 (DuoBody®-CD40x4-1BB) is an investigational, novel, agonistic, bispecific antibody that combines targeting and conditional activation of CD40 and 4-1BB on immune cells for priming and (re-) activation of tumor-specific immune responses. Acknowledgements This trial was funded by Genmab A/S and BioNTech SE. com Our proprietary antibody platforms DuoBody® Bispecific antibodies Dec 11, 2024 · The Genmab DuoBody bsAb data analysis procedure and time savings obtained by the adoption of the automated MS-based data analysis workflow. The clinical success of immune checkpoint inhibitor monoclonal antibodies (mAbs) has demonstrated potential for re-activation of anti-tumor immunity in cancer treatment. Rooted in science, Inspired by patients Visit Genmab. Global DuoBody is an innovative platform for discovering and developing bispecific antibodies, also called dual-targeting molecules. Based on these findings, the low CD3 affinity bsAb was selected for follow-up studies and named DuoBody-CD3xB7H4 (GEN1047). GEN1042 demonstrated biologic and early clinical activity with a manageable safety profile in patients (pts) with advanced solid tumors in the dose escalation part of the ongoing phase 1/2 trial May 20, 2023 · Epcoritamab由Genmab研发，采用Duobody双抗技术平台构建，在两条重链的CH3分别引入K409R和F405L突变，体外通过Fab exchange 形成双特异性抗体。 Epcoritamab通过募集T细胞杀伤CD20阳性肿瘤细胞。 2020 Nov 19, 2024 · 使用Genmab DuoBody 控制的抗原结合片段(Fab)臂交换过程组合亲本mAb，产生对每种抗原具有单臂结合位点（即单价）的双特异性抗体。 此外，亲本mAb是在工程化细胞系中产生的，该细胞系将低水平的岩藻糖掺入Fc区，以增强抗体与免疫效应细胞上的FcR的结合，从而促进抗肿瘤免疫细胞定向活性。 Mar 8, 2022 · Genmab A/S (Nasdaq: GMAB) announced today that the U. 16 Bredgade 34 Fax: +45 7020 2729 Page 1/2 1260 Copenhagen K, Denmark www. These technology Nov 16, 2021 · Genmab’s proprietary DuoBody and HexaBody antibody technology platforms are mostly in phase 1 of development, and Darzalex’s royalties will supply more than enough cash to fund these programs. The innovative DuoBody technology We discovered that the introduction of a mutation in the Fc domain of IgG1 antibodies, such as at the E345 or E430 positions, reinforces inter-antibody Fc-Fc interactions, thereby stimulating antibody hexamer formation (Figure 1). Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells News for GEN1044 / Genmab, AbbVie. DuoBody is Sep 21, 2016 · DuoBody platform是其中的一种双特异性抗体生成技术平台，能够快速、稳定以及规模化生产的双特异性抗体。 DuoBody platform操作相对简单，仅需在两个IgG1抗体的Fc Nov 29, 2018 · Based on these data, Genmab has initiated a First-in-Human clinical trial to evaluate the safety and preliminary efficacy of DuoBody-CD3xCD20 by subcutaneous Copenhagen, Denmark; August 14, 2015 — Genmab A/S (OMX: GEN) announced today it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody Dec 11, 2024 · Genmab is an international biotechnology company that specializes in creating and developing antibody biotherapeutics for treating cancer. Jun 10, 2020 · Genmab’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies (ASH 2022) - "In the last decade, treatment regimen including brentuximab vedotin have significantly improved prognosis for patients with CD30-expressing lymphomasHere, we report preclinical data for the novel Apr 30, 2018 · for the DuoBody technology with BioNovion (subsequently acquired by Aduro Biotech) and BioNTech, enabling Genmab to enter one of the hottest areas in cancer research at present. DuoBody-CD3x5T4 is a bispecific IgG1 antibody with a functionally inactive Fc Acasunlimab (GEN1046/BNT311) is an investigational PD-L1x4-1BB bispecific antibody fusing Genmab's proprietary DuoBody ® technology platform and BioNTech’s proprietary immunomodulatory Discover how Genmab makes a positive impact for patients, communities, employees and the environment. Use the options below to choose which trials you wish to view. Aug 17, 2015 · DuoBody is Genmab's platform for antibodies called bispecific because they bind to two different epitopes, either on the same target or different targets. According to Genmab, bispecific antibodies generated through DuoBody may Sep 21, 2016 · Duobody技术除了可以用来制备双特异性抗体，同样可以用于开发基于Fc片段的双靶向融合蛋白等产品。DuoBody Platform pipeline Genmab的pipeline上有十余种蛋白产品进入了临床阶段，包括单克隆抗体、双特异性抗体以及抗体偶联药物。 May 8, 2018 · Genmab’s DuoBody platform generates bispecific antibodies via a fast and broadly applicable process, which is easily performed at standard bench, as well as commercial manufacturing scale. Here, we investigated whether VHHs can be applied to generate Jan 12, 2025 · Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody ® platform for generation of bispecific antibodies, the HexaBody ® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce Background Checkpoint inhibitors targeting the PD-1/PD-L1 axis (CPI) have changed the treatment paradigm and prognosis for patients with advanced solid tumors; however, many patients experience limited benefit due to treatment resistance. Genmab, Utrecht, NJ, Netherlands. Learn more. It is hypothesized that teclistamab will induce T cell–mediated cytotoxicity through recruitment of Oct 28, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Genmab, Utrecht, Netherlands. Previously, we described encouraging preclinical and Dec 8, 2024 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Bispecific antibodies bind to two different epitopes (or "docking Dec 8, 2024 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Developed by Genmab, cFAE is used to generate bsAbs termed DuoBodies (DBs). pharnexcloud. Our Responsibility. 2102 3884 Company Announcement • Genmab to receive $4 million milestone payment in DuoBody® collaboration with Janssen • 2013 financial guidance improved Jan 23, 2024 · For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www. May 8, 2018 · GENMAB ENTERS DUOBODY TECHNOLOGY COLLABORATION Genmab A/S Tel: +45 7020 2728 Company Announcement no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122. 8 billion in cash. Patricia Garrido Castro. 38 CVR no. About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and Sep 30, 2023 · Genmab revenue increased 26% compared to the first nine months of 2022, to DKK 11,796 million; Genmab 2023 financial guidance updated “With regulatory approvals in Japan and Europe, EPKINLY/TEPKINLY is the first Genmab-owned medicine to become available to patients outside of the United States. By bridging different cells together, bispecific antibodies can Dec 2, 2016 · To target cancer cells expressing BCMA, we developed a BCMAxCD3 bispecific antibody using the Genmab DuoBody® technology (Ab-957) to recruit T cells to BCMA-expressing MM cells so that T cells could be Dec 21, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. Apr 14, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Acasunlimab (GEN1046/BNT311) is an investigational PD-L1x4-1BB bispecific antibody fusing Genmab's proprietary DuoBody ® technology platform and BioNTech’s proprietary immunomodulatory antibodies. OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (OmniAb) - "Genmab expects to announce acasunlimab (GEN1046: PD-L1 x 4-1BB) Phase 2 data in second-line non-small cell lung cancer (NSCLC) in the first half of 2024; A poster titled 'Acasunlimab (duobody-PD-L1x4-1BB) alone or in combination with pembrolizumab in May 1, 2020 · We therefore evaluated in this study the preclinical activity of the novel fully human BCMA×CD3 bispecific antibody (JNJ-7957), which was developed using the Genmab DuoBody technology and has silenced Fc function to eliminate Fc-dependent immune effector functions . Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed. 43 were able to show high product purity of the VHH/Fab bispecific DuoBody format for three different model antibodies. : daratumumab, daratumumab Sep 25, 2014 · Labrijn et al. DuoBody is based on the naturally occurring process of Fab-arm exchange. Today, several DBs are in clinical development and amivantamab, a bispecific molecule targeting epidermal growth factor receptor (EGFR) and cMET that is partnered with Janssen, was recently approved by the FDA to treat adult patients with locally advanced or metastatic Dec 20, 2011 · Genmab’s proprietary DuoBody platform creates human bispecific antibodies which bind to two different epitopes, on the same or different disease targets. Trial Registration May 3, 2024 · Genmab has used the DuoBody platform as the basis of four approved bispecific antibody medicines. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic 3 days ago · Conclusions DuoBody-CD40×4-1BB demonstrated biologic and early antitumor activity with a favorable safety profile in patients with advanced solid tumors. However, toxicity and a narrow therapeutic window have hampered their clinical development. Several clinical trials are currently underway to investigate the effectiveness of CD3 bispecific antibodies (bsAb) in solid tumors. Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody-CD3xB7H4 in solid cancer models (SITC 2022) - P1/2 | "Currently, DuoBody-CD3xB7H4 is being investigated in a first-in-human clinical trial for the treatment of solid tumors known to express B7H4 ( NCT05180474 ), in which the MoA and PD, including biomarkers of Dec 2, 2016 · To target cancer cells expressing BCMA, we developed a BCMAxCD3 bispecific antibody using the Genmab DuoBody® technology (Ab-957) to recruit T cells to BCMA-expressing MM cells so that T cells could be activated and induced to kill BCMA + cancer cells. Acasunlimab (GEN1046/BNT311) is an investigational PD-L1x4-1BB bispecific antibody fusing Genmab's proprietary DuoBody ® technology platform and BioNTech’s proprietary immunomodulatory Jun 26, 2024 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Detailed visualization and reporting delivering deeper insights into sample makeup Using MS-based methods, mass calculations provide an additional level of confidence in the identification of each molecular Acasunlimab (GEN1046/BNT311) is an investigational PD-L1x4-1BB bispecific antibody fusing Genmab's proprietary DuoBody ® technology platform and BioNTech’s proprietary immunomodulatory Mar 11, 2021 · GEN1042 (DuoBody-CD40x4-1BB) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology. Our Impact. com Page 1/2 2500 Valby, Denmark CVR no. 2102 3884 Company Announcement - Additional DuoBody™ technology collaboration - USD 2 million upfront payment to Genmab DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB to enhance priming and reactivation of tumor-specific immunity in patients with cancer. Highly prevalent 5T4 expression in solid tumors (Fig S1 and Table S1) and reported limited expression in normal tissues (Southall et al, 1990; Ali et al, 2001; Alam et al, 2018) suggest that 5T4 could be a promising target for an anticancer therapeutic. With its ability to confer clinical benefit in tumors typically less sensitive to CPIs, GEN1046 may fill a clinical gap in CPI-relapsed Epcoritamab is being co-developed by Genmab and AbbVie Inc. DuoBody-CD3xB7H4 demonstrated antitumor activity in vivo in a PDX screen in HIS mice. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T Background: DuoBody®-CD3xCD20 (GEN3013) is a full-length human IgG1 bispecific antibody (bsAb) recognizing CD3 and CD20, generated by controlled Fab-arm exchange. The company has about 20 products in clinical development that incorporate hexamer technology. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic Nov 3, 2022 · About Epcoritamab Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. DuoBody molecules that feature bispecificity can be administered and dosed as other antibody therapeutics. Acasunlimab is designed to elicit an antitumor response via conditional activation of 4-1BB on T cells and natural killer cells, which is strictly May 8, 2018 · Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale. (DuoBody® CD3xCD20) Induces Durable, Complete Apr 3, 2024 · Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody Nov 6, 2024 · 艾可瑞妥单抗采用Genmab公司的DuoBody专利技术生产，该技术旨在将细胞毒性T细胞选择性导向肿瘤，以诱发对恶性肿瘤细胞的免疫反应。 作为一款双 Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The Nov 21, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Given the number of approved CD3 bsAb therapies thus far, the development of these bsAbs appears to be more challenging in solid cancer compared to hematological malignancies. Hiemstra & Esther C. We connect with partners to expand our capabilities and deep knowledge of the power of the human immune Mar 6, 2015 · Genmab has learned how to apply the Fab arm exchange process that occurs naturally with IgG4 antibodies to its Duobody bispecific IgG1 format, by matching point mutations at the interface between Apr 13, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. com CVR no. . About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and Nov 29, 2018 · DuoBody®-CD3xCD20 (GEN3013) is a bispecific antibody (bsAb), recognizing the T-cell antigen CD3 and the B-cell antigen CD20, that triggers potent. The DuoBody technology platform is capable of generating bispecific antibodies which are dual targeting Nov 27, 2024 · heterodimer formation facilitated by the CH -domain mutations produces a stable, bispeci c antibody. View all articles by this author. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization Background Agonistic 4-1BB monoclonal antibodies were preclinically validated as promising cancer immunotherapies, both as monotherapy and as potentiators of the activity of PD-(L)1–blocking agents. Sep 21, 2016 · DuoBody platform是其中的一种双特异性抗体生成技术平台，能够快速、稳定以及规模化生产的双特异性抗体。 DuoBody platform操作相对简单，仅需在两个IgG1抗体的Fc CH3区域分别引入K409R和F405L突变位点，混合两 DuoBody is a versatile platform for the discovery and development of bispecific IgG antibodies. Genmab's DuoBody-CD3 technology is designed to Nov 21, 2024 · DuoBody-ADC(Genmab)，由Genmab A/S (Genmab A/S)公司最早进行研发，目前全球最高研发状态为终止，治疗领域: 肿瘤。Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated May 21, 2024 · Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ®; the Y-shaped Genmab logo ®; Genmab in combination with the Y-shaped Genmab logo ®; HuMax ®; DuoBody ®; HexaBody ®; DuoHexaBody ®, HexElect ® and KYSO ®. Browse all the issues in Volume 18 of Nature Reviews Drug Discovery May 21, 2024 · Genmab has completed acquisition of ProfoundBio for USD 1. Genmab DuoBody Ab Technology • DuoBody Abs are made by controlled Fab arm exchange of matched CH3 mutations • K409R and F405L are destabilizing mutations in the CH3 interface • The complementary mutations favor heterodimerization. Jul 18, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Securities and Exchange Commission (SEC), which are available Mar 8, 2022 · Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. 2The agent targets PD-L1 and 4-1BB, selected to block inhibitory PD-1/PD-L1 axis and Dec 9, 2023 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2023. Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan involving Genmab products. The study is currently enrolling (EudraCT No: 2017-001748 May 20, 2021 · Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Jan 3, 2025 at 07:56 PM CET This page is a resource for Genmab investors, potential shareholders and analysts to access corporate and financial information Nov 12, 2020 · GEN1046 is a proprietary bispecific antibody that was developed using Genmab’s DuoBody technology. Genmab’s innovation: • Janssen Biotech, Inc. HexaBody ®-CD38 developed in exclusive worldwide license and option agreement with Janssen Biotech, Inc. ) 2007-03-29 Filing date 2008-03-28 Publication date 2015-12-15 2008-03-28 Application filed by Genmab AS filed Feb 15, 2024 · Company Announcement. Tisotumab vedotin is being co-developed by Genmab and Pfizer Inc. Thereby, DuoBody-CD40×4-1BB strengthened the dendritic Aug 16, 2015 · Genmab’s DuoBody platform is a proprietary technology platform for the discovery and development of bispecific antibodies, which binds to two different epitopes either on the same or on different targets. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic Dec 4, 2020 · Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody ® platform for generation of bispecific antibodies, the HexaBody ® platform Genmab’s DuoBody platform swiftly generates bispecific antibodies through a process performed at standard bench, in addition to commercial, manufacturing scale. Results DuoBody- CD40×4- 1BB exhibited conditional CD40 and 4-1BB agonist activity that was strictly dependent on crosslinking of both targets. Ida H. com显示，一项针对DuoBody-PD-L1x4-1BB的2期 Apr 28, 2020 · Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell malignancies. GEN1046 (DuoBody®-PD-L1x4-1BB) is an investigational, potential first-in-class bispecific immunomodulatory antibody designed to elicit an anti-tumor immune response by simultaneous and complementary blockade of PD-L1 on tumor or immune cells and conditional 4-1BB stimulation on T cells and NK cells. targets PDIt -L1 and 4-1BB, selected to block the inhibitory PD1/PD-L1 axis and simultaneously conditionally activate essential co-stimulatory activity Apr 15, 2022 · Epcoritamab由Genmab研发，采用Duobody双抗技术平台构建，在两条重链的CH3分别引入K409R和F405L突变，体外通过Fab exchange 形成双特异性抗体。Epcoritamab通过募集T细胞杀伤CD20阳性肿瘤细胞。2020年5 Jan 22, 2024 · Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen Genmab A/S Tel: +45 7020 2728 Company Announcement no. The antitumor efficacy was tested in MM cell lines and in BM samples obtained Jun 10, 2022 · DuoBody-CD40×4-1BB (GEN1042/BNT312) is a novel investigational Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB to enhance priming and reactivation of tumor-specific immunity in patients with cancer. Bispecific antibodies have the potential Nov 7, 2022 · 6. Epcoritamab, a phase Jun 28, 2023 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. describe the generation of bispecific antibodies through controlled Fab-arm exchange, involving separate expression of two parental IgG1s containing single matching point mutations May 14, 2024 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. 5 Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse La. Furthermore, we entered a new DuoBody technology agreement with Novo Nordisk outside the cancer field. It is being co-developed under an agreement in Mar 9, 2022 · Provide oncologists and hematologists with a 3D animation of Genmab’s DuoBody™ technology platform and visually explain the science of bispecific antibodies: single molecules that can bind specifically and simultaneously to two different targets, such as receptors or ligands. About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and May 22, 2021 · This is the first regulatory approval for a product that was created using Genmab’s proprietary DuoBody ® technology platform. Under the agreement with Janssen, Genmab will receive royalties on Mar 2, 2020 · Genmab拥有4类抗体药物研发平台：基于UltiMAb的裸抗体药物平台HuMAb、 双特异性抗体平台DuoBody 、增强型抗体平台HexaBody以及强增强型抗体平台HexElect。此外，Genmab还与ADC Therapeutics（ADCT）达成合作，共同开发基于公司HuMax-TAC的 DuoBody®-CD3xCD20 (GEN3013) is a full-length human IgG1 bispecific antibody (bsAb) recognizing CD3 and CD20, generated by controlled Fab-arm exchange. Patient Engagement. 02 Carl Jacobsens Vej 30 www. Repeated dosing of DuoBody-CD3xB7H4 in cynomolgus monkeys confirmed an acceptable safety profile up to the maximal dose tested (30 mg/kg). DuoBody® is Genmab’s versatile platform technology for discovering and developing bispecific antibodies, also called dual-targeting molecules. By restricting the activation of desired mechanisms of action to cell surfaces co-expressing combinations of two targets, the therapeutic index (the ratio of Fourth regulatory approval for a therapy created using Genmab’s proprietary DuoBody ® bispecific technology platform April 27, 2023 Genmab enters partnership with argenx as a steppingstone to broaden its vision beyond May 8, 2018 · Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale. Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial Genmab’s proprietary pipeline was inspired by leveraging our own cutting-edge scientific capabilities, innovative scientific approach, translational medicine laboratory expertise and strategic partnerships. 1: DuoBody-CD40x4-1BB (GEN1042/BNT312) Companies developing products created by Genmab or that incorporate . Genmab, Copenhagen, Denmark. 54 Bredgade 34E Fax: +45 7020 2729 Page 1/3 1260 Copenhagen K, Denmark www. Jun 11, 2022 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic Dec 6, 2018 · Genmab A/S Tel: +45 7020 2728 Company Announcement no. Jan 11, 2022 · Developed by Genmab, cFAE is used to generate bsAbs termed DuoBodies (DBs). Apr 4, 2023 · Abstract. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T Jul 1, 2021 · Abstract. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic News for GEN3017 / Genmab. Company Announcement no. Keywords: Bispecific antibody, CD3, CD20, T cell redirection, B cell malignancy, Subcutaneous administration. Its Fc domain was silenced by introduction of mutations L234F L235E D265A. Expansion cohorts, including combination therapy with PD-1 inhibitors, are cur-rently enrolling. : tisotumab vedotin (Tivdak ®) • AbbVie Inc. DuoBody ®-CD40x4-1BB, DuoBody ®-EpCAMx4-1BB, and HexaBody ®-OX40 are being co-developed by Genmab and BioNTech. As the Aug 9, 2023 · DuoBody是genmab的双特异性抗体技术平台。这几年连续有三个基于DuoBody的双特异性抗体上市，包括：Amivantamab、Teclistamab和Talquetamab，这每一个都是如雷贯耳呐。之前可能很多人都不太想了解，但 Mar 10, 2015 · Genmab’s DuoBody platform creates bispecifics using “a mechanism that nature has developed that spontaneously produces bispecific antibodies,” explained van de Winkel, mimicking the process Genmab introduces DuoBody ®, a next-generation bispecific antibody technology platform that could be applied to potential therapies that may target cancer and other serious diseases 2012 Genmab introduces HexaBody ® , a novel antibody technology platform that enables differentiated therapies by enhancing the natural target-killing abilities The DuoHexaBody ® platform is Genmab’s proprietary technology that combines the dual targeting of our DuoBody ® technology with the enhanced potency of our HexaBody ® technology, creating bispecific antibodies with target-mediated enhanced hexamerization. HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and Sep 9, 2022 · Generation of DuoBody-CD3x5T4. W. DuoBody-CD40×4-1BB is being jointly developed by Genmab and BioNTech for the treatment of solid Dec 10, 2023 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Company Announcement • Co-development agreement with BioNovion • Bispecific antibodies to immuno-oncology targets to be created with DuoBody Technology Copenhagen, Denmark; February 19, 2015 – Genmab A/S (OMX: GEN) Aug 12, 2024 · Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and administered subcutaneously. DuoBody 强生／杨森，在2012年选择了与Genmab的DuoBody双抗平台进行合作，DuoBody双抗构建体是通过Fab臂交换产生的，它利用CH3-CH3抗体界面的突变和重组，将两个独立mAbs的重链和轻链同源物结合成一 Jun 9, 2022 · DuoBody-PD-L1x4-1BB（GEN1046）是Genmab 与BioNTech共同开发的靶向PD-L1和4-1BB的双特异性抗体，用于治疗实体瘤。药融圈旗下，药融云数据www. Breij Jul 8, 2020 · Genmab’s now partnered epcoritamab (DuoBody-CD3xCD20) and DuoBody-CD3x5T4 are T-cell-engaging therapeutics that direct cancer-killing T cells to cancer antigens of interest. Genmab. iaaim yym rgxjy bjdo fvrfn vefu alq iejn wlhjyu cqdkvh
